Grant Title: UNDERSTANDING AND TREATING CO-MORBID CONDITIONS IN ADOLESCENTS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (R01, R03, R21)

Funding Opportunity Number: PA-11-039, PA-11-040, PA-11-041. CFDA Number(s): 93.865.

Agency/Department: National Institutes of Health.

Area of Research: Investigator-initiated research upon the factors that impact functioning and quality of life in individuals with intellectual and developmental disabilities (IDD) during adolescence.


Application Deadline: R01-New: February 5, June 5, October 5 annually; Renewal, resubmission, revision: March 5, July 5, November 5 annually; R03, R21-New: February 16, June 16, October 16 annually; Resubmissions: March 16, July 16, November 16 annually.

Amount: R01: Typically under $500,000 per year in direct costs; if request equals or exceeds $500,000, prior approval is required; R03: $50,000 per year; maximum of $100,000 over a 2 year period; R21: $275,000 direct costs for the 2 year period.

Length of Support: R01: Up to 5 years; R03: 2 years; R21: 2 years.

Eligible Applicants: Public and State controlled institutions of higher education. See the full announcement for a complete list of eligible applicants.

Summary: The objective of this (FOA) is to create a more substantial base of evidence to inform future research directions in studies of adolescents with IDD and to better meet the medical, psychosocial, and psychiatric needs of a growing population of individuals with IDD in the United States and internationally. Some examples of research topics include: Comparative studies to address plasticity in specific brain circuits during adolescence; interventions that may enhance neural plasticity and adaptive brain reorganization, thereby promoting significant improvement in functioning and quality of life; evaluation of psychiatric conditions that occur in the general adolescent population to determine if these conditions are different or similar in IDD populations; studies on medical comorbid conditions that may be particularly difficult to manage in IDD populations; development of validated outcome measures for use in randomized controlled trials of treatments and/or interventions; innovative treatments and/or interventions that improve functioning and quality of life in adolescents with IDD and address distinctive characteristics that may be unique to specific IDD conditions or that specifically target symptoms unique to adolescence; adaptation of evidence-based interventions to reduce or ameliorate symptoms and improve adaptive functioning; multi-site randomized controlled trials of comprehensive interventions, addressing co-morbidities, family functioning, and community involvement; informative outcome measures that contribute in a meaningful way to understand common and specific features of transitions that occur during adolescence in IDD populations; studies that address the creation of a medical home that ensures preventive care and health promotion in the transition from adolescence to young adult life for individuals with IDD; development of comprehensive, culturally competent assessments of family needs to foster youth autonomy and family support; studies of coping strategies of families from disparate ancestral backgrounds that influence the effects of interventions and treatments to provide general improvement in quality of life and those that may be more successful in specific cultural contexts; studies that focus on the impact of health disparities with respect to access to medical care, medical and psychiatric diagnoses, and/or compliance issues with medications and/or specific behavioral or medical interventions to better understand the impact of adolescence on future morbidity and mortality in specific IDD populations.